Retrospective Analysis On Hospitalization And Health Care Costs, According To Serum Uric Acid Levels In Patients From A Sample Of Italian Local Health Units

Abstract

Objectives: To estimate the cumulative incidence and hospital cost for venous and pulmonary thromboembolic events in a real world setting in France. MethOds: We conducted a retrospective analysis of the EGB database, a 1/97th random sample of the whole National health insurance database records linked to hospitalizations. All patients hospitalized in 2010 and 2011 with a diagnosis of deep vein thrombosis (DVT) or pulmonary embolism (PE) were included. Inpatients were identified through principal diagnosis of hospitalization stay. Outpatients with a DVT were identified by 1) an echo Doppler exam, 2) preceded or followed by a low molecular weight heparin or fondaparinux delivery (+/-7 days), and 3) a subsequent Vitamin K antagonists delivery (0 to 7 days). Incidences and annual hospital cost of DVT and PE were estimated and extrapolated to the overall French population, and cumulative proportions of recurrences were calculated. Results: For 2011, the estimated crude incidences were 141/100,000 (91,650 patients) for DVT, and 79.4/100,000 for PE (51,610 patients in France). Mean age of patients was 67.0+/-17.2 years for PE and 64.1+/-17.7 years for DVT. A majority of patients were females (57% in both groups). After index event (PE/DVT), the cumulative proportions of venous thromboembolic recurrences were 2.6% at 1 month, 3.7% at 3 months, 5.1% at 6 months and 6.7% at 12 months. The cumulative proportions of death after a PE and a DVT first event were 0.2% at 1 month, 1.1% at 3 months, 2.6% at 6 months and 6.2% at 12 months. Annual hospital cost of venous and pulmonary thromboembolic events was estimated at 712 million € (362 million € for DVT and 350 million € for PE). cOnclusiOns: In 2011, around 143,000 patients suffered from venous and pulmonary thromboembolic events in France. Hospitalized events accounted for an important burden in France.